Symbol="ELYM"
AssetType="Common Stock"
Name="Eliem Therapeutics Inc"
Description="Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other central nervous system disorders. and peripheral in the United States. The company is headquartered in Redmond, Washington."
CIK="1768446"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="23515 NE NOVELTY HILL ROAD, SUITE B221 #125, REDMOND, WA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="73152000"
EBITDA="None"
PERatio="None"
PEGRatio="None"
BookValue="4.332"
DividendPerShare="0"
DividendYield="0"
EPS="-1.94"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.174"
ReturnOnEquityTTM="-0.4"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.94"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="4.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.494"
EVToRevenue="-"
EVToEBITDA="1.202"
Beta="None"
num_52WeekHigh="4.75"
num_52WeekLow="2.21"
num_50DayMovingAverage="2.868"
num_200DayMovingAverage="3.105"
SharesOutstanding="26993400"
DividendDate="None"
ExDividendDate="None"
symbol="ELYM"
open="2.71"
high="2.71"
low="2.59"
price="2.65"
volume="11255.00"
latest_trading_day="2023-08-04"
previous_close="2.71"
change="-0.06"
change_percent="-2.2140%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="65"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="35"
Volume_recent_avg="20590"
Change_recent_avg="0.01"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="0.29"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="35"
Aroon_momentum_negative="65"
image_negative_thumbnail_id_1="1129"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0162.jpeg"
image_negative_thumbnail_id_2="518"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0087.jpeg"
image_neutral_thumbnail_id_1="591"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0008.jpeg"
image_neutral_thumbnail_id_2="526"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0073.jpeg"
image_positive_thumbnail_id_1="1008"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0170.jpeg"
image_positive_thumbnail_id_2="602"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0106.jpeg"
image_professor_thumbnail_id_1="1167"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
image_professor_thumbnail_id_2="1192"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
